(N 4 • Me-MMdCyd) and 5-methoxymethyl-N 4-methyl-2'deoxycytidine-5 were synthesized to confer resistance to deamination by deaminating enzymes. N 4-Me-MMdCyd and N 4-Me-' MMdCMP were inactive against Herpes simplex virus type 1 (HSV-1) and also nontoxic to VERO cells up to 1796 J.LM (highest concentration tested). 5methoxymethyl-2'-deoxycytidine-5'-monophosphate (MMdCMP) was more potent than the nucleoside against HSV-1 in VERO cells. In HSV-infected VERO cells (10 PFUlcell), N 4-Me-MMdCyd caused only slight perturbations of deoxyribonucleoside triphosphate pools. 5-methoxymethyl-N 4-methyl-2' -deoxycytidine-5'-triphosphate (N 4-Me-MMdCTP) was synthesized and the nature of interaction of N 4-Me-MMdCTP and dCTP with DNA polymerase of Escherichia coli, HSV-1 and human Q'. was investigated. N 4-Me-MMdCTP was neither an effective substrate nor a strong inhibitor of Escherichia coli, HSV-1 or human Q'. DNA polymerase.
Introduction
Nucleoside analogues with selective activity against Herpes simplex virus (HSV) 1 are presently of major interest and are a considerable focus of research. This new generation of antivirals includes acyclic guanosines (ACV, DHPG), 5-substituted-2'-deoxyuridines (BrVdUrd, EtdUrd, MMdUrd) , and 2'-fluoro-5-substituted-arabinosylpyrimidines (FIAC, FEAU) . The selectivity of these nucleoside analogues is due to preferential phosphorylation by virus-induced deoxypyrimidine nucleoside kinase to the monophosphate (Fyfe et al., 1978; Lopez et al., 1980; Cheng et al., 1981; DeClercq, 1982; Gupta et al., 1987) . After conversion to the triphosphates, they specifically inhibit viral DNA polymerase and are also incorporated into the viral DNA (Allaudeen et al., 1981 (Allaudeen et al., , 1982 Ruth and Cheng, 1981; Mancini et aI., 1983; Otto and Prusoff, 1984; Reid et ei., 1987; Aduma et aI., 1991a) . In spite of the recent advances in the discovery of drugs which elicit antiviral activity by selectively utilizing or inhibiting virusspecified metabolic functions to a greater degree than host cells, there is a definite need for better drugs to treat HSV-associated diseases for the following reasons: 5substituted deoxyuridine analogues (BrVdUrd, EtdUrd), though potent antiherpes agents, are rapidly catabolized to inactive pyrimidine bases by thymidine and/or uridine phosphorylases (Desgranges et al., 1983; Veres et aI., 1986) .Thus, these compounds are of limited usefulness in 1 Abbreviations used are: ACV (acyclovir), 9-[(2-hydroxymethoxy)methyl] guanine; DHPG, 9-[(1,3-dihydroxyprop-2-oxy)methyllguanine; BrVdUrd, (E)-5-(2-bromovinyl)-2' -deoxyuridine; BrVdCyd, (E)-5-(2-bromovinyl)-2'deoxycytidine; EtdUrd, 5-ethyl-2'-deoxyuridine; MMdUrd, 5-methoxymethyl-2' -deoxyurldlne: FIAC, 2' -f1uoro-5-iodo-arabinofuranosylcytosine; FEAU, 2'-f1uoro-5-ethyl-arabinofuranosyluracil; MMdCyd, 5-methoxymethyl-2'-deoxycytidine; MMdCMP, 5-methoxymethyl-2'-deoxycytidine-5'monophosphate; MMdCTP, 5-methoxymethyl-2'-deoxycytidine-5'-triphosphate; N 4-Me-MMdCyd, 5-methoxymethyl-N 4-methyl-2' -deoxycytidine; N 4-Me-MMdCMP, 5-rnethoxymethyl-N 4-methyl-2' -deoxycytidine-5'-monophosphate; N 4-Me-MMdCTP, s-metnoxymethyl-Nt-metnyl-z'> deoxycytidine-5' -triphosphate; IdCyd, 5-iodo-2'-deoxycytidine; H4dUrd, tetrahydrodeoxyuridine; HSV-1, herpes simplex virus type 1; dNTP, deoxyribonucleoside triphosphate. the treatment of systemic HSV infections, and currently approved drugs, such as acyclovir, adenine arabinoside, and trifluorothymidine, are not effective in preventing latency or emergence of HSV from latency.
Our hypothesis is that it should be possible to overcome these limitations by the use of deoxycytidine (dCyd) analogues provided these compounds can be channelled through the dCyd kinase-deoxycytidylate (dCMP) kinase pathway in HSV-infected cells (Fig. 1) . The rationale for these hypotheses are: that dCyd analogues are not a substrate of pyrimidine nucleoside phosphorylases and therefore would be metabolically stable; that dCyd analogues should be selectively virotoxic because they would be incorporated as such into the viral DNA, and that 5-substituted dCyd analogues should also have desirable effects in preventing latency or emergence from latency in recurrent infections. The hypothesis is based on the premise that as analogues of 5-methylcytosine (amodified base found in both eukaryotic and some viral DNAs)these compounds are likely to interfere with the processes of synthesis of nonmethylated DNAwhich appears to playan important part in virus maturation and productive infection (Sharma and Biswal, 1977) . Thus, when maintained in the deoxycytidine form, 5-substituted dCyd analogues should prove to be superior therapeutic agents forthe treatment of HSV infections as compared to their corresponding deoxyuridine analogues.
A major drawback for the therapeutic use of cytidine compounds is their tendency to undergo deamination in the presence of deaminating enzymes. These enzymes are usually present in blood and mammalian cells and catalyse the deamination of cytidine compounds to the corresponding uridine analogues, which are either less active (Camiener and Smith, 1965) or do not display selectivity towards HSV-infected cells (Fox et aI., 1983) . When deamination of IdCyd was prevented by co-administration with H 4dUrd 2 , it was incorporated as such into the DNA of HSV-infected cells as well as cells transformed with a restriction fragment containing the HSV dThd kinase (Fox et al., 1983) . We have reported that when deamination was prevented, the antiviral potency of BrVdCyd and especially MMdCyd is greatly enhanced (Aduma et aI., 1990a (Aduma et aI., , 1990b . Hadtlrd is an inhibitor of both Cyd/dCyd deaminase and dCMP deaminase. This transient state analogue is anabolized by a phosphotransferase to its corresponding nucleotide, H 4dUMP, which is a potent inhibitor of dCMP deaminase (Maley and Maley, 1971) . Under these conditions, dCyd analogues would be phosphorylated without deamination to their corresponding trlphosphates in HSV-infected cells. For example, preferential utilization of MMdCTP relative to dCTP by HSV-1 DNA polymerase and its eventual incorporation into HSV DNA seems to be responsible for the antiviral action of MMdCyd (Aduma et al., 1991a) . Deoxycytidine analogues resistant to deaminases would have the advantage of simplifying treatment regimens. Resistance to deamination can be attained by structural modification of the molecule (Dolinger et al., 1967; Wang et al., 1973; Mancini and Lin, 1983) . Of considerable interest is the recent report that 2',3'dideoxy-Nl-methyl-adenosine was resistant to adenosine deaminase and active against human immunodeficiency virus, an aetiological agent of AIDS (Chu et al., personal communication). Fox et al. (1983) have shown that alkyl derivatives of IdCyd (N 4-methyl, ethyl and isopropyl) were incorporated into viral DNA, albeit to a small degree, without deamination. This led us to synthesize the methyl derivative of MMdCyd (N 4-Me-MMdCyd). The conformational changes induced by N 4-methyl substitution and its effect on antiviral activity are discussed in this paper.
Results

Biological activity
The antiviral activity of MMdCyd, N 4-Me-MMdCyd, MMdCMP and N 4-Me-MMdCMP in VERa cells against HSV-1 was determined. MMdCyd and MMdCMP were active against HSV-1. The antiviral potency of MMdCMP was higher [(50% effective dose ED 50 ) 10-14 fLM] than MMdCyd (ED 5o 19-26 fLM). In contrast, N 4-Me-MMdCyd and N 4-Me-MMdCMP were devoid of antiviral activity up to 1796 fLM (the highest concentration tested). These results indicate that the lack of activity of N 4-Me-MMdCyd was not necessarily due to a lack of phosphorylation to the 5' -monophosphate by viral dThd/dCyd kinase. All compounds were noncytotoxic to VERa cells up to 1796 fLM.
The effect of N 4-Me-MMdCyd on the dNTP pool sizes are shown in Table 1 . MMdCyd was included as a positive control. In HSV-infected VERa cells, N 4-Me-MMdCyd caused slight perturbations of both pyrimidine and purine nucleotide pools. The only substantial change was an expansion of the dTIP pool from 303 pmol (control) to 419 pmol (treated cells). These changes may be indicative of some effect of N 4-Me-MMdCyd on virus-specific events. However, it is lnterestlnq to note, that alterations of dNTP pools occurring in the presence of N 4-Me-MMdCyd were minor compared to the effect of MMdCyd, the active antimetabolite, on dNTP pools. In uninfected cells, treatment with N 4-Me-MMdCyd resulted in expansion of purine nucleotide pools, whereas dCTP and dTIP pools were not affected.
MMdCTP is utilized as an alternate substrate by bacterial DNA polymerase and HSV-1 DNA polymerase (Aduma et aI., 1991a) .Therefore, studies were undertaken
Proposed pathways for metabolism of 5-substituted deoxycytidine analogues in HSVinfected cells. Tetrahydrodeoxyuridine (H4dUrd) inhibits both cytidine deaminase and deoxycytidylate deaminase. Tetrahydrouridine (H4Urd) inhibits cytidine deaminase. 1: dThd/ dCyd kinase (virus-induced); 2: dCyd deaminase; 3: dCMP deaminase; 4: dThd and/or Urd phosphorylase; 5: dTMP synthase; 6: DNA polymerase (Virus-induced). Inhibition -.
to examine whether N 4-Me-MMdCTP could serve as a substrate for DNA polymerase. N 4-Me-MMdCTP (up to 5 fLM) was not utilized for DNA synthesis by Escherichia coli DNA polymerase I. Furthermore, N 4-Me-MMdCTP did not affect the utilization of dCTP by the bacterial enzyme (Table 2 ). These results indicate that N 4-Me-MMdCTP lacks affinity for the Escherichia coli enzyme. The nature of interaction of N 4-Me-MMdCTP with HSV-1 and human a DNA polymerase was also studied. The results of these experiments are expressed as percentage incorporation of [3H]-dATP in the presence of N 4-Me-MMdCTP relative to that of 10 fLM dCTP (Table 3) . Increasing the concentration of N 4-Me-M MdCTP up to 10 fLM had no observable effect on DNA synthesis. The values for HSV-1 DNA polymerase (12%) and human DNA polymerase a (38%) indicate that limited DNA synthesis occurred in the presence of the three natural dNTPs. Also, there was no decrease in DNA synthesis in the presence of 10 fLM N 4-Me-MMdCTP when dCTP was 10 fLM. These results indicate that there was little, if any, competition with the utilization of dCTP by HSV-1 and human DNA polymerase a.
The structural formulae for MMdCyd and N 4-Me-MMd-Cyd are shown in Fig. 2 . In order to get a better understanding of the relationship between antiviral activity and molecular structure, the two' molecules were compared using the computer program PROFIT (Smith, 1983 (Gupta et si., 1991; Jia et aI., 1990 Jia et aI., , 1990a .
; Enzymatic assays were carried out with 1 unit of Escherichia coli DNA polymerase I. dTTP, dGTP and l"HjdATP were used at 5 fLM in easy assay. ;;N 4-Me-MMdCTP (0.625 fLM) was used with each concentration of dCTP. ;;; cpm values are net after subtractlnq '0' samples which did not contain the nucleotides. 
Discussion
Studies with MMdCyd in combination with deaminase inhibitors have shown that this antimetabolite has potent activity against HSV-1 and low cytotoxicity (Gupta et el., 1991; Aduma et al., 1990b) . We hypothesized that selectivity of MMdCyd is due to anabolism by the dCyd-kinase pathway in HSV-infected VERO cells to its corresponding triphosphate, MMdCTP; which is preferentially utilized as a substrate by the viral DNA polymerase and after its 
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incorporation into the DNA inhibits genome replication (Gupta et al., 1989 (Gupta et al., , 1991 Aduma et al., 1991a) . In addition, perturbations of dNTP pools (precursors required for DNA synthesis) on treatment with MMdCyd plus H 4dUrd also contribute to the antiviral activity (Gupta et aI., 1989 (Gupta et aI., , 1991 Aduma et al., 1991b) .The complete loss of antiviral activity by alkylation at the N 4-position of MMdCyd was unexpected and surprising. It has been reported that alkyl derivatives of IdCyd (N 4-methyl, ethyl, and isopropyl) were incorporated into viral DNA without deamination (Fox et aI., 1983) . This can only occur if these compounds were metabolized using dCyd kinase-dCMP kinase pathway in HSV-infected cells to the triphosphate level. Therefore, it was reasoned that the loss of activity could be due to the following: N 4-Me-MMdCyd is not phosphorylated by HSV-induced pyrimidine nucleoside kinase to its corresponding monophosphate, N 4-Me-MMdCMP; N 4-Me-MMdCMP is not further phosphorylated to the triphosphate, N 4-Me-MMdCTP; and N 4-Me-MMdCTP does not serve as a substrate or inhibitor of HSV-induced DNA polymerase. Thus, a lack of affinity for either the viral kinase or the DNA polymerase would be sufficient to render the molecule inactive. In order to provide answers to these questions, N 4-Me-MMdCMP and MMdCMP were initially synthesized and their antiherpes activity was determined. N 4-Me-MMdCMP was devoid of antiherpes activity. Interestingly, MMdCMP was approximately 2-fold more potent than MMdCyd against HSV-l in VERO cells. N 43-Me-MMdCTP was synthesized and its interaction with purified DNA polymerases from Escherichia coli, 
C(5') 0(5') N(1)* C(2)* 0(2)* N(3)* C(4)* N(4)* C(5)* C(5,1)* 0(5,2) C(5,3) C(6)* C(1')* C(2') C(3') 0(3') C(4') 0(4') C(5') 0(5') HSV-1 and human IX was investigated. N 4-Me-MMdCTP failed to serve as a substrate or inhibitor of these DNA polymerases. In marked contrast, MMdCTP is preferentially utilized by HSV-1 DNA polymerase and is also a competitive inhibitor of the viral enzyme with respect to dCTP (Gupta et al., 1991; Aduma et al., 1991a) .Thus, even if N 4-Me-MMdCMP could be converted to N 4-Me-MMdCTP in HSV-infected VERO cells, its lack of affinity for the viral DNA polymerase suggests that viral replication most likely would not be impeded. Studies from our laboratory have shown that the conformation of the deoxyribose moiety is important in determining substrate specificity towards the HSVinduced thymidine kinase Tourigny et al., 1989) .Therefore, the crystal structure of MMdCyd and N 4-Me-MMdCyd was determined (Jia et aI., 1990 (Jia et aI., , 1990a . Interestingly, and unexpectedly, the conformation of the deoxyribofuranose ringe in MMdCyd and N 4-Me-MMd-Cyd was found to be different. In N 4-Me-MMdCyd, the exocyclic C(5') side chain has the tconformation, whereas in MMdCyd, it has the g+ rotomer conformation.
Previous studies have shown that 2' -deoxyribonucleosides with the t rotomer as the more stable conformation are not readily phosphorylated by HSV-induced· dThd/ dCyd kinase compared to the substrates with the g+ rotomer conformation . Furthermore, the N 4-methyl group may impede binding to the viral kinase by steric hindrance and/or by hindering hydrogen bonding between the enzyme and the lone pair of electrons at N(3) [the N 4-methyl group is eisoidal to N(3)]. Similarly, it is conceivable that the orientation of the N 4-methyl group may prevent incorporation into DNA by HSV DNA polymerase by prevention of hydrogen bonding to N(4). As well, the change in the conformation of the deoxyribose moiety may interfere with binding to the deoxyribonucleoside triphosphate binding site of HSV DNA polymerase. N 4-Me-MMdCyd was devoid of cytotoxicity. The lack of affinity of N 4-Me-MMdCTP for DNA polymerase IX could partly account for the lack of cellular toxicity of N 4-Me-MMdCyd. It is also probable that N 4-Me-MMdCyd is not phosphorylated by cellular kinases and this would also contribute to the lack of cytotoxicity. N 4-Me-MMdCyd does have an effect on the metabolism of uninfected cells as evidenced by the approximately 100% increase in purine deoxyribonucleotide triphosphate pools. It also had an effect on the dNTP pool sizes in virus-infected VEROcells. It is interesting to note, however, that none of these changes in dNTP pools produced any observable biological effects. Cytotoxicity was not observed and viral replication was not affected. The reason for the changes in dNTP pool sizes and whether these changes can be exploited for antiviral activity is not clear at this time.
In conclusion, it is apparent from these studies that a seemingly minor structural alteration in a molecule can alter completely its biological properties. The change in the conformation of the sugar moiety was not expected to occur as a result of methylation of the N 4-position of MMdCyd. As more antivirals are developed and more conformations determined, it should be possible then to predict conformational changes that could occur as a result of a particular chemical modification. The ability to make such predictions would enable the rational development of better drugs for the treatment of viral diseases.
These results indicate that attempts to render resistance to deamination by akylation at the N 4-position of the cytosine moiety is not likely to yield compounds with anti-HSV activity.
Materials and experimental procedures
Drug inhibition assays VERO cells were grown in Eagle's minimum essential medium (MEM) containing 10% foetal bovine serum (FBS) as previously described (Ayisi et a/., 1980; Aduma et a/., 1990a) . Confluent monolayers were prepared by seeding 5 x 10 4 cells into each well of a microtitre (96-well) tissue culture plate. The cultures were incubated at arc in a humidified CO 2 (5%) amtosphere. Cells were regularly checked for mycoplasma contamination and only cells free of mycoplasma were used. Stocks of HSV-1 strain KOS were prepared on VERO cells, titrated and maintained as described previously (Aduma et aI., 1990a) . Antibodies against HSV-1 were prepared (Ayisi et aI., 1980) . Antiviral activity was determined by the plaque reduction method (Ayisi et et., 1980; Aduma et a/., 1990a) . Briefly, confluent monolayers were infected with 50 plaque forming units (PFU) of virus per well in a microtitre tray. After incubation at arc for 1 h to allow virus adsorption; unadsorbed virus was removed by washing with MEM, and immediately thereafter, exposed to increasing concentrations of the test compounds in MEM containing 4% FBS. Plaques were allowed to develop for 72 h before fixation, staining and enumeration. From dose response curves, the concentration required to reduce the number of plaques by 50% (ED so) was determined. In each experiment, toxicity controls (containing test compound and medium only), cell controls (containing media only) and virus controls (containing virus and media) were run in simultaneously.
Analysis of deoxyribonueleoside triphosphate (dNTP) pools
The dNTP pools, in uninfected and HSV-infected VERO cells, were determined by enzymatic assay based on the method of Solter and Handschumacher (1969) with minor modifications. Confluent monolayers of VERO cells were infected with HSV-1, KOS strain at a multiplicity of infection of 10 PFU per cell. The procedure for infection, extraction and enzymatic analysis has been described (Aduma et a/., 1991b) . The amount of N 4-Me-MMdCyd used in these treatments was 500fLM. The lowest amount of dNTP detectable by the enzyme assay was 0.5 pmol. Results were analysed by a one-way analysis of variance. MMdCyd was run concurrently as a positive control. r In vitro DNA synthesis with DNA polymerase
The ability of N 4-Me-MMdCTP to serve as a substrate for DNA synthesis was determined using DNA polymerases from Escherichia coli, HSV-1 and human Qt. The assay conditions were:
Bacterial DNA polymerase activity. This was assayed by studying incorporation of FHldATP (5 fLM) in the presence of dGTP (5fLM), dTIP (5fLM) and 0.039 to 5 fLM N 4-Me-MMdCTP or dCTP (positive control). The assay mixture consisted of 50mM Tris pH 7.5, 5mM MgCI 2 , 10 fL9 activated calf thymus DNA, 20 fL9 bovine serum albumin (BSA), 10% glycerol, and 1 unit of Escherichia coli DNA polymerase I. In the second set of experiments each concentration of dCTP (0.039 to 5 fLM) was run in the presence of a fixed amount of N 4-Me-MMdCTP (0.625 fLM) in order to examine the effects of the N 4-Me-MMdCTP on utilization of the natural metabolite (dCTP).Total reaction volume was 200fLi.
HSV-1 DNA polymerase activity. This was assayed using 50 mM Tris pH 8.5, 2mM dithiothreitol, 4mM MgCI 2 , 50mM ammonium sulphate, 10 fL9 activated calf thymus DNA, 20 fL9 BSA, 10% glycerol, the enzyme and the nucleotides. The concentration of dGTP, dTIP and FHldATP was 10 fLM and varying concentrations of N4-Me-MMdCTP (0-10 fLM). Positive controls consisting of 10fLMdCTP were run simultaneously. Total reaction volume was 100 ul.
Human DNA polymerase Qt. The assay mixture contained 50 mM Tris pH 8.0, 2 mM dithiothreitol, 8 mM MgCb, 10 fL9 activated calf thymus DNA, 20fL9 BSA, 10% glycerol, the enzyme and nucleotides. The amounts of cold and radiolabelled nucleotides used were similar as described for the HSV-1 enzyme. dCTP (10 fLM) was used as the positive control. Total reaction volume was 100 fLl.
lncubations of the assay mixture were carried out at 3rC for 30 min and the reaction was stopped by transferring allquots into 1ml ice-cold 5% TCA. The acid-insoluble precipitate was collected by filtration on Whatman GF/F glass filters. The filters were washed successively with 5% TCA, followed with 95% ethanol, air dried and counted in a liquid scintillation counter (Beckman, model LS 3800). The reaction was linear over this time period. All assays were run in triplicate.
Chemicals and Biologicals: Escherichia coli DNA polymerase I, activated calf thymus DNA and cold dNTPs were purchased from Sigma Chemical Co. (St. Louis, MO). Radiolabelled [rnethyl-Pl-l] thymidine-5'-triphosphate (FHldTIP, SA 46Ci rnrnol") was obtained from Amersham (Oakville, Ontario). [8-3H(N)deoxyadenosine-5'-triphosphate, (FHldATP, SA 19.1 Ci mrnol") was purchased from DuPont Canada. Purified HSV-1 DNA polymerase (from HSV-1, strain HF) and human DNA polymerase Qt (from KB cells) were gifts from Dr Allaudeen NIH, MD. All chemicals were of highest purity. The procedure for synthesis of MMdCyd (FW 271) and N 4-Me-MMdCyd (FW 285) have been described (Jia et al., 1990 and .
Synthesis of 5-methoxymethyl-2'-deoxycytidine-5'-monophosphate (MMdCMP) and . General Procedure: POCI 3 (0.8 mmol) was slowly added to a chilled solution of the nucleoside (0.4 mmol) in trimethylphosphate and the reaction mixture was stirred for 18-20h at 4°C under anhydrous conditions. The monophosphodichloridate solution was added slowly to water, neutralized with triethylamine and Conformation and antiviral ectivity-ll 21 extracted 3x with ethyl ether. The aqueous phase was chromatographed on a DEAESephadex A-25 (carbonate form; 2.5 x 15em) column and the effluent was monitored at 254nm and 280nm.
After loading, the column was washed with water until the absorption of the effluent reached the base line. The monophosphate derivatives were eluted with triethylammonium bicarbonate (50mM, pH 7.5). Appropriate fractions were pooled and lyophilized. MMdCMP (yield 50%); U.V. A m ax (0.1M HCI) 284nm (E 12500) and N 4-Me-MMdCMP (yield 45%); U.V. A m ax (0.1M HC!) 283nm (E 13400). The products were pure (>95%) as judged by HPLC and DEAE paper chromatography. The gummy residue was stored as such or reconstituted in water and stored in small aliquots at -20°C. MMdCMP and N 4-Me-MMdCMP were stable under these storage conditions.
Synthesis of 5-methoxymethyl-2'-deoxycytidine-5'-triphosphate (MMdCTP) and . Nucleoside triphosphates were synthesized using the procedure described previously (Aduma et al., 1991) . The yield of N 4-Me-MMdCTP was 10-12% based on absorption at A m ax 283nm (0.1 M HCI) and using an extinction coefficient of 13400. The product was pure (95%) as judged by HPLC and DEAE cellulose paper chromatography. The lyophilized residue was dissolved in water and stored in small aliquots at -20°C. N 4-Me-MMdCTP was stable under these conditions.
